On December 22, 2020 Polymed Biopharma reported that it recently submitted two patent applications for the discovery of novel PROTAC molecules for treatment of cancer and autoimmune diseases (Press release, Polymed Biopharmaceuticals, DEC 22, 2020, View Source [SID1234630612]). These molecules have demonstrated activities in the degradation of target proteins and proliferation inhibition of disease model cell line. Polymed plans to further study the safety and effectiveness of these molecules in related animal disease models.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!